[Enoxaparin in haemodialysis].
Using of low-molecular-weight heparins (LMWH) in haemodialysis therapy significantly reduced the incidence of haemorrhagic complications with the same clinical efficacy in comparison to standard unfractionated heparins. Taking enoxaparin as example, we present the mechanisms of action of LMWH paying special attention to efficacy in haemodialysis and adverse effects.
Olszowska
Anna
A
Klinika Nefrologii ze Stacja Dializ Centralnego Szpitala Klinicznego WAM w Warszawie.
Zelichowski
Grzegorz
G
D000925:Anticoagulants / Q000627:therapeutic use*; D017984:Enoxaparin / Q000627:therapeutic use*; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000188:drug therapy / Q000628:therapy*; D006435:Renal Dialysis / Q000009:adverse effects* / Q000379:methods; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control*
D000925:Anticoagulants; D017984:Enoxaparin; D005343:Fibrinolytic Agents